**Supplementary Table 6** Comparisons of EQ-5D-5L scores on the day before surgery (preoperative) and at three weeks postoperatively (early post-discharge) between the propofol-based TIVA and DES groups.

<table>
<thead>
<tr>
<th></th>
<th>Preoperative</th>
<th>Early post-discharge</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DES (n = 70)</td>
<td>TIVA (n = 70)</td>
</tr>
<tr>
<td>Mobility</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No problems</td>
<td>63 (90.0)</td>
<td>64 (91.4)</td>
</tr>
<tr>
<td>Slight problems</td>
<td>5 (7.1)</td>
<td>6 (8.6)</td>
</tr>
<tr>
<td>Moderate problems</td>
<td>1 (1.4)</td>
<td>0</td>
</tr>
<tr>
<td>Severe problems</td>
<td>1 (1.4)</td>
<td>0</td>
</tr>
<tr>
<td>Extreme problems or</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>unable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Self-care</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No problems</td>
<td>68 (97.1)</td>
<td>68 (97.1)</td>
</tr>
<tr>
<td>Slight problems</td>
<td>2 (2.9)</td>
<td>1 (1.4)</td>
</tr>
<tr>
<td>Moderate problems</td>
<td>0</td>
<td>1 (1.4)</td>
</tr>
<tr>
<td>Severe problems</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Extreme problems or</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>unable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Usual activities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No problems</td>
<td>64 (91.4)</td>
<td>65 (92.9)</td>
</tr>
<tr>
<td>Slight problems</td>
<td>5 (7.1)</td>
<td>4 (5.7)</td>
</tr>
<tr>
<td>Moderate problems</td>
<td>1 (1.4)</td>
<td>1 (1.4)</td>
</tr>
<tr>
<td></td>
<td>DES</td>
<td>EQ-5D-5L</td>
</tr>
<tr>
<td>--------------------------</td>
<td>-----------</td>
<td>--------------</td>
</tr>
<tr>
<td>Severe problems</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Extreme problems or</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>unable</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Pain/discomfort</strong></td>
<td><strong>0.818</strong></td>
<td><strong>0.572</strong></td>
</tr>
<tr>
<td>No problems</td>
<td>51 (72.9)</td>
<td>53 (75.7)</td>
</tr>
<tr>
<td>Slight problems</td>
<td>17 (24.3)</td>
<td>16 (23.2)</td>
</tr>
<tr>
<td>Moderate problems</td>
<td>2 (2.9)</td>
<td>1 (1.4)</td>
</tr>
<tr>
<td>Severe problems</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Extreme problems or</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>unable</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Anxiety/depression</strong></td>
<td><strong>0.758</strong></td>
<td><strong>0.547</strong></td>
</tr>
<tr>
<td>No problems</td>
<td>36 (51.4)</td>
<td>36 (51.4)</td>
</tr>
<tr>
<td>Slight problems</td>
<td>30 (42.9)</td>
<td>28 (40.0)</td>
</tr>
<tr>
<td>Moderate problems</td>
<td>4 (5.7)</td>
<td>5 (7.1)</td>
</tr>
<tr>
<td>Severe problems</td>
<td>0</td>
<td>1 (1.4)</td>
</tr>
<tr>
<td>Extreme problems or</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>unable</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Visual analog scale</strong></td>
<td><strong>0.607</strong></td>
<td><strong>0.178</strong></td>
</tr>
<tr>
<td>health today, mm (0–100)</td>
<td>80 (70, 90)</td>
<td>80 (70, 85)</td>
</tr>
</tbody>
</table>

Values are expressed as number of patients (%) and median (Q1, Q3).

DES: desflurane anesthesia, EQ-5D-5L: EuroQol five-dimension instrument with a five-level scale, TIVA: total intravenous anesthesia